Israel and New Jersey-based 101 Therapeutics Ltd. has released Phase II/III clinical data for its macrophage-targeted dexamethasone prodrug 101-PGC-005, and simultaneously called for emergency evaluation of the therapy in Bundibugyo Ebola disease, a viral hemorrhagic fever for which no approved vaccine or species-specific therapeutic currently exists. The company published the results as a medRxiv preprint rather than waiting for peer review, arguing that the urgency of the ongoing outbreak warrants immediate consideration of the data by regulators, ethics committees, and outbreak-response organizations.
The request is unusual because 101-PGC-005 has never been studied in Ebola virus disease. Instead, the company is relying on data from a 309-patient adaptive randomized Phase II/III trial in severe COVID-19-associated inflammatory disease, where it reported superiority to dexamethasone on the primary endpoint and multiple secondary endpoints, no treatment-related serious adverse events, and preservation of hypothalamic-pituitary-adrenal axis function. The company also reported no detectable free dexamethasone in plasma, urine, or cerebrospinal fluid, supporting its claim that the drug delivers glucocorticoid activity selectively to activated macrophages while minimizing systemic steroid exposure.
101-PGC-005 is designed for uptake by activated CD206-positive macrophages, a cell population implicated in pathological inflammatory responses across multiple severe infectious and inflammatory conditions. The company's argument is not that the drug has demonstrated efficacy against Ebola virus itself, but that a therapy capable of selectively dampening macrophage-driven hyperinflammation could warrant evaluation in a disease characterized by cytokine storm, immune dysregulation, and vascular injury. Unlike virus-directed therapies, a host-directed approach would not depend on species-specific viral targeting.
The outbreak context is central to the company's case. Bundibugyo Ebola disease currently lacks any approved vaccine or dedicated therapeutic, leaving supportive care as the standard of treatment. Regeneron's maftivimab, the most potent neutralizing antibody component of Inmazeb, has been identified by the World Health Organization as a candidate for evaluation based on cross-neutralization data, but no therapy has yet been approved specifically for Bundibugyo virus disease.